INDEGENE
Back to Balance Sheet
|
INDEGENE Last 5 Year Total Non-Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹56 Cr | ₹435 Cr | ₹584 Cr | ₹80 Cr | ₹27 Cr |
What is the latest Total Non-Current Liabilities ratio of INDEGENE ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2025 | ₹56 Cr |
| Mar2024 | ₹435 Cr |
| Mar2023 | ₹584 Cr |
| Mar2022 | ₹80 Cr |
| Mar2021 | ₹27 Cr |
How is Total Non-Current Liabilities of INDEGENE Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹56 Cr | -87.12 | |
| Mar2024 | ₹435 Cr | -25.54 | |
| Mar2023 | ₹584 Cr | 630.10 | |
| Mar2022 | ₹80 Cr | 198.58 | |
| Mar2021 | ₹27 Cr | - | |
Compare Total Non-Current Liabilities of peers of INDEGENE
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| INDEGENE | ₹12,430.4 Cr | -2.6% | 6.7% | -5.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹447,032.0 Cr | 0.9% | 12.8% | 4.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹183,759.0 Cr | 3.2% | 14% | 13.2% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹149,224.0 Cr | 0.7% | 5.5% | 36.9% | Stock Analytics | |
| CIPLA | ₹116,214.0 Cr | 6.8% | 18.8% | -10.2% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹108,739.0 Cr | 0.7% | 5.5% | 9.4% | Stock Analytics | |
INDEGENE Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| INDEGENE | -2.6% |
6.7% |
-5.5% |
| SENSEX | -3.1% |
-2.8% |
-6.1% |
You may also like the below Video Courses